Key Highlights

  • 6.51% is the indicated pre-market move for PRF Technologies Ltd. (NASDAQ:PRFX) on November 17, 2026, taking the indicated price to USD 0.7400 from a calculated prior close of USD 0.6948.
  • 30 consecutive Business days, from September 24 to November 4, 2026, of closing bids below USD 1.00 led Nasdaq staff to issue a delisting determination dated November 9, 2026.
  • 2026 third quarter end cash and short-term deposits were about USD 11.0 million on a preliminary, unaudited basis as of September 30, 2026, giving a small-cap healthcare and energy company some runway.
  • 5 is the ratio of the reverse share split effected on February 6, 2026, which made PRF Technologies Ltd. (NASDAQ:PRFX) ineligible for the usual 180 day compliance period.

What Moved PRF Technologies Ltd. (NASDAQ:PRFX) in Pre-Market Trading on November 17, 2026 (+USD 0.0452, +6.51%)

The indicated pre-market price on November 17, 2026 is USD 0.7400, a pre-market move of +6.51%. On a calculated basis, the prior close was USD 0.6948 (price divided by 1.0651) and the USD move is +USD 0.0452 (price minus prior close). The indicated price remains below the USD 1.00 minimum bid level that Nasdaq applies to Capital Market issuers. No pre-market Volume or Liquidity figures were found in published coverage. The company, formerly known as PainReform, is based in Tel Aviv, Israel, with a healthcare platform built on a proprietary extended-release drug-delivery system and an energy platform built around AI-driven optimization.

The Rationale: Nasdaq Hearing Request and GridFeed Term Sheet for PRF Technologies Ltd. (NASDAQ:PRFX)

No single catalyst for the move was identified, but the recent news flow is dense. The company received a Nasdaq letter on November 9, 2026 and announced on November 12, 2026 that it had requested a hearing before a Nasdaq Hearings Panel, which stays the suspension and delisting while the Panel decides. The hearing request deadline was 4:00 p.m. ET on November 16, 2026. The Panel can grant an exception of up to 180 days from the determination, or until May 8, 2027, and the company plans to present a compliance plan that may include a further reverse share split. Separately, a non-binding term sheet signed on November 3, 2026 contemplates a GridFeed transaction with Dotz Nano Limited, with no definitive agreements executed.

Valuation, Liquidity and Risks for PRF Technologies Ltd. (NASDAQ:PRFX)

Cash and short-term deposits were about USD 11.0 million as of September 30, 2026, on a preliminary and unaudited basis. The healthcare business includes majority-owned LayerBio, which expects to begin enrolling patients in the Phase 2 OcuRing-K trial before year-end 2026 after FDA IND clearance announced on April 28, 2026. A corroborated market Capitalization and share count were not found, but a sub-USD 1.00 share price signals a small-cap with elevated risk. The company itself states there can be no assurance that the Panel will grant continued listing. Reverse splits, possible dilution from future financing, clinical-stage uncertainty and an unsigned GridFeed deal are all specific risks.

Where Things Stand

PRF Technologies (NASDAQ:PRFX) is indicated at USD 0.7400 in pre-market trading on November 17, 2026, up +6.51% from a calculated prior close of USD 0.6948. The stock sits at the center of a listing dispute, with 30 consecutive business days below USD 1.00, a delisting determination dated November 9, 2026 and a hearing request that keeps the shares trading on the Nasdaq Capital Market. Cash of about USD 11.0 million at September 30, 2026 provides some runway, while the Panel window to May 8, 2027 and the non-binding GridFeed term sheet with Dotz Nano Limited leave outcomes open.